Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Oxford Lane Capital Corp — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while Oxford Lane Capital Corp trades at $8.56 (market cap $835.71M). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 7.2× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 28.15% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Oxford Lane Capital Corp for 50 Days on average.
| IOVA | OXLC | |
|---|---|---|
Market Cap | $6.04B | $835.71M |
Volume | 14,805,993 | 1,125,263 |
Sector | Health | Financials |
52-Week High | $14.82 | $16.74 |
52-Week Low | $1.81 | $8.15 |
Typical Hold Time | 0 Days | 50 Days |
Enterprise Value | $5.97B | $1.23B |
Dividend Yield | — | 28.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
OXLC trades at $8.56, up 1.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The stock shows a low P/B of 0.81 and pays a consistent $0.20 monthly dividend. However, recent earnings have significantly missed expectations, with a Q1 2026 loss of -$6.23 per share, and 2026 revenue and net profit trends are deeply negative, raising sustainability concerns.
The outlook is highly speculative. The deep discount to book value and high dividend yield present a potential value opportunity for income-focused investors, but this is offset by severe profitability erosion, negative cash flow from operations, and analyst skepticism. Key risks include the company's ability to stabilize its net asset value and fund its dividend without further capital erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
